MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-26-2026
OncoCyte Corporation DPO Ratio 2011-2026 | OCX
Annual DPO Ratio OncoCyte Corporation
| 2025 | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 436 | - | 635 | 587 | 85 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 635 | 85 | 436 |
Quarterly DPO Ratio OncoCyte Corporation
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 880 | 966 | - | 2.04 K | 2.79 K | 337 | - | 577 | - | - | - | 623 | 1.26 K | 225 | 74.9 | 121 | 73.7 | 94.2 | 55.1 | 65.6 | 108 | 238 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.79 K | 55.1 | 619 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M |  USA |
 |
Compugen Ltd.
CGEN
|
82.7 | $ 2.59 | -5.31 % | $ 242 M |  Israel |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
405 | $ 0.91 | 3.25 % | $ 6.69 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
75.2 | $ 22.57 | -0.44 % | $ 3.74 B | USA |
 |
Evogene Ltd.
EVGN
|
62.6 | $ 0.78 | -0.66 % | $ 27.9 M | Israel |
 |
Fennec Pharmaceuticals
FENC
|
894 | $ 6.33 | -5.52 % | $ 181 M | USA |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Galapagos NV
GLPG
|
81.9 | $ 27.94 | -1.69 % | $ 2.69 B |  Belgium |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M | Israel |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | USA |
 |
Aquestive Therapeutics
AQST
|
395 | $ 4.06 | -0.73 % | $ 434 M | USA |
 |
Jaguar Health
JAGX
|
676 | $ 0.23 | -5.44 % | $ 536 K | USA |
 |
Arcutis Biotherapeutics
ARQT
|
133 | $ 22.63 | -2.86 % | $ 2.88 B | USA |
 |
KalVista Pharmaceuticals
KALV
|
1.03 K | $ 26.73 | 38.9 % | $ 1.44 B | Britain |
 |
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.42 | -4.39 % | $ 378 M | Britain |
 |
Kamada Ltd.
KMDA
|
106 | $ 8.14 | -0.09 % | $ 260 M | Israel |
 |
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B | Britain |